Oncology & Cancer

CAR T therapy shows long-lasting remissions in non-hodgkin lymphoma

A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah, researchers ...

Medications

FDA approves venetoclax for chronic lymphocytic leukemia

(HealthDay)—Venetoclax (VENCLEXTA) has been approved to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma, the U.S. Food and Drug Administration announced yesterday.

Oncology & Cancer

New genetic mutations found for non-Hodgkin lymphoma

Scientists at the BC Cancer Agency in British Columbia, Canada and their U.S. collaborators have identified a number of new genetic mutations involved in non-Hodgkin lymphoma, or NHL.

Oncology & Cancer

A new, potent weapon against lymphomas

MDC researchers have developed a new approach to CAR T-cell therapy. The team has shown in Nature Communications that the procedure is very effective, especially when it comes to fighting follicular lymphomas and chronic ...

page 2 from 12